Apoptosis

Apoptosis is a peer-reviewed international journal published by Springer, founded in 1996 and devoted to basic and clinically oriented research into programmed cell death, with a 2025 Journal Impact Factor of 9.0《细胞凋亡》（Apoptosis）是由（Springer）出版的同行评审国际期刊，1996 年创办，专注程序性细胞死亡的基础与临床研究，2025 年影响因子为 9.0。

Scope

• The journal is devoted to the rapid publication of innovative basic and clinically oriented investigations into programmed cell death该刊致力于快速发表程序性细胞死亡的创新性基础与临床研究。
• It aims to stimulate research on the mechanisms of apoptosis and their role in human disease其旨在推动细胞凋亡机制及其在人类疾病中作用的研究。
• Disease areas include cancer, autoimmune disease, viral infection and AIDS涉及的疾病领域包括癌症、自身免疫病、病毒感染与艾滋病。
• Cardiovascular disease, neurodegenerative disorders, osteoporosis and ageing are also covered心血管疾病、神经退行性疾病、骨质疏松与衰老也在收录之列。
• The journal encourages the development of clinical therapies against apoptosis-related diseases该刊鼓励针对凋亡相关疾病的临床疗法研发。
• It publishes original research, reviews and short communications on cell death mechanisms该刊发表关于细胞死亡机制的原创研究、综述与短篇通讯。
• Work spanning the molecular biology, biochemistry and cell biology of cell death is within scope涵盖细胞死亡分子生物学、生物化学与细胞生物学的研究均在其范围内。

History

• The journal was founded in 1996 and published its first volume that year, with Volume 1 appearing in four issues该刊创办于 1996 年，同年出版第一卷，第一卷共四期。
• It was originally published in London by Rapid Science Publishers before moving to the publisher's current imprint该刊最初由伦敦（Rapid Science Publishers）出版，后转至现出版方。
• From 2005 it has been published from Dordrecht, Netherlands, by Springer, and it remains a Springer title today自 2005 年起由（Springer）在荷兰多德雷赫特出版，至今仍是其旗下期刊。
• It is indexed in MEDLINE from Volume 5, 2000, and is abstracted in PubMed and the Science Citation Index Expanded该刊自 2000 年第 5 卷起被（MEDLINE）收录，并被（PubMed）与（SCIE）摘要收录。
• Its Journal Impact Factor rose from 4.677 in 2021 and 5.561 in 2022 to 8.1 in 2024 and 9.0 in 2025其影响因子由 2021 年的 4.677 与 2022 年的 5.561 升至 2024 年的 8.1 与 2025 年的 9.0。
• The journal is published monthly and follows a hybrid publishing model with both subscription and open access options该刊以月刊出版，采用订阅与开放获取并行的混合出版模式。

Editors

• Arjan W. Griffioen of Vrije Universiteit Amsterdam, Netherlands, is an editor-in-chief based in the Department of Medical Oncology主编（Arjan W. Griffioen）来自荷兰（Vrije Universiteit Amsterdam），任职于肿瘤内科。
• Patrycja Nowak-Sliwinska of the University of Geneva, Switzerland, is the other editor-in-chief in the School of Pharmaceutical Sciences另一位主编（Patrycja Nowak-Sliwinska）来自瑞士（University of Geneva），任职于药学院。
• The associate editors include Wolfram Brune of the Leibniz Institute of Virology, Peng Luo of Xijing Hospital and Ratna B. Ray of Saint Louis University副编辑包括（Leibniz Institute of Virology）的（Wolfram Brune）、（Xijing Hospital）的（Peng Luo）与（Saint Louis University）的（Ratna B. Ray）。
• Further associate editors are Carol Troy of Columbia University, Hao Zhang of Chongqing Medical University and Boris Zhivotovsky of Karolinska Institutet其他副编辑包括（Columbia University）的（Carol Troy）、（Chongqing Medical University）的（Hao Zhang）与（Karolinska Institutet）的（Boris Zhivotovsky）。
• The editorial board has over forty members from countries including the United States, the Netherlands, France, Germany and China编委会拥有四十余名成员，来自美国、荷兰、法国、德国与中国等国家。
• The journal is peer reviewed, and authors may choose to publish open access under a Creative Commons license该刊实行同行评审，作者可选择以开放获取方式发表并采用知识共享许可协议。